Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Deals
|
M&A
|
Financials
|
Strategy
|
Lifecycle Management
|
Legal
|
Business
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Tekmira and Pfizer sign siRNA delivery deal
Today
Tekmira Pharmaceuticals ' shares rose by 24% on news that it has agreed an RNA drug delivery deal with Pfizer . The Canadian firm's shares closed at 87 cents each on Tuesday and opened up by one percent soon after the markets opened yesterday. The firms will use Tekmira's stable nucleic acid-lipid particle (SNALP) technology to deliver small interfering RNA molecules provided by Pfizer. Tekmira will provide the formulations and Pfizer will evaluate them in preclinical models. Tekmira's SNALP ...
 
Tekmira and Pfizer sign siRNA delivery deal
Today
Tekmira Pharmaceuticals ' shares rose by 24% on news that it has agreed an RNA drug delivery deal with Pfizer . The Canadian firm's shares closed at 87 cents each on Tuesday and opened up by one percent soon after the markets opened yesterday. The firms will use Tekmira's stable nucleic acid-lipid ...
Leespharm gains Chinese rights to Zanidip
17 March 2010
The Hong Kong-based healthcare company Lee's Pharmaceutical Holdings(Leespharm) has acquired an exclusive licence for the marketing and sale of Recordati 's antihypertensive Zanidip (lercanidipine) in China. The once-daily calcium antagonist was launched in this market in 2002 and has been sold ...
 
Astellas puts forward board nominees in OSI bid
17 March 2010
Astellas has now drawn up a full set of independent directors for nomination for election at the upcoming annual general meeting of its acquisition target OSI Pharmaceuticals . The move forms part of Astellas's bid to get round opposition to its currently proposed deal from OSI's incumbent board ...
Elan sells Prialt to ex-execs' firm Azur
17 March 2010
Elan is to sell the rights to its pain infusion drug Prialt (ziconotide) to Azur Pharma, a company set up by former executives of the Irish pharmaceutical group in 2005. Dublin, Ireland-based Azur will acquire all rights globally except for Europe, which were acquired by Eisai in 2006. Financial ...
 
Hikma has $400 million to make acquisitions this year
Today
Hikma Pharmaceuticals is in a position to carry out acquisitions worth up to $400 million in total this year, CEO Said Darwazah has told Scrip. "In 2009 we were actively engaged with certain companies and we should see those talks come to fruition this year," he added. Hikma has earmarked three ...
Olainfarm is to open Bangkok office to expand in Asia
17 March 2010
Latvia's second-largest pharmaceutical manufacturer Olainfarm is to open a representative office in Bangkok, Thailand, to maintain sales growth in Asia and diversify risks. Its chairman Valerijs Maligins said that the opening of the new office, which will control operations in Vietnam and ...
 
Hikma has $400 million to make acquisitions this year
Today
Hikma Pharmaceuticals is in a position to carry out acquisitions worth up to $400 million in total this year, CEO Said Darwazah has told Scrip. "In 2009 we were actively engaged with certain companies and we should see those talks come to fruition this year," he added. Hikma has earmarked three ...
Olainfarm is to open Bangkok office to expand in Asia
17 March 2010
Latvia's second-largest pharmaceutical manufacturer Olainfarm is to open a representative office in Bangkok, Thailand, to maintain sales growth in Asia and diversify risks. Its chairman Valerijs Maligins said that the opening of the new office, which will control operations inVietnam and ...
 
Merck/Portola's betrixaban shows bleeding benefit in Phase IIb
16 March 2010
Merck / Portola Pharmaceuticals ' investigational Factor Xa inhibiting anticoagulant betrixaban was associated with significantly less clinically relevant bleeding than warfarin when given at 40mg/day to patients with atrial fibrillation, show new results from a dose-finding study presented on ...
Counterfeiters beware: WHO shows poor countries how to procure antimalarials
10 March 2010
Establishments that produce substandard or counterfeit antimalarials will find it harder to sell their products to developing countries after the World Health Organization published new guidelines this week spelling out how to buy quality-made artemisinin-based combination therapies (ACTs), the ...
 
KV unit Ethex pleads guilty to two felonies in oversize pill case
09 March 2010
KV Pharmaceutical unit Ethex Corp pled guilty on March 2nd in the US District Court for the Eastern District of Missouri to two felonies in connection with the manufacturing of oversized prescription drug tablets, according to the US Justice Department. The government charged that, despite having ...
AstraZeneca awaits decision in US Crestor patent case
08 March 2010
AstraZeneca has a lot riding on the outcome of US patent litigation relating to its cholesterol therapy, Crestor (rosuvastatin). It failed last December in its attempt to gain summary judgement on allegations of inequitable conduct in the obtainment of the active ingredient patent ('314), and as a ...
 

Executive Briefing – Health technology assessment: a brief look at the EU
31 December 2009

Global demographic developments are forcing countries to scrutinise their healthcare sectors and ...

 Market Insight - Fear gives way to prudence a...
 How to run clinical trials in the Middle East...

2010 Scrip 100 - Scrip PharmaMetrics
09 December 2009

Deals speak volumes about company sentiment and the overall health of the pharmaceutical industry. ...

2010 Scrip 100 - Can Piramal do a 'Nano' for Indian pharma?
09 December 2009

The launch of a new small car has shown the world that India can innovate. The couple in charge of ...

European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Elizabeth Sukkar
Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Face-to-face with Abingworth's Stephen Bunting:we've had time to adapt to tough markets
25 August 2009
Sukaina Virji
While many venture capital (VC) firms have dropped beneath the radar during the current credit ...

Your Career in Pharma
26 September 2008
The choosy candidate, Can translational medicine deliver? and MHRA in the frame

Scrip's Stock Tracker February 2010
12 March 2010
Ashley Yeo
Talk of dividends being under threat at companies such as Bristol-Myers Squibb , Pfizer and Lilly , ...

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm